Results of the Phase 3, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus as maintenance therapy in advanced sarcoma patients following clinical benefit from prior standard cytotoxic chemotherapy
https://www.powershow.com/view/3ba7f0-MDk3Y/Results_of_the_Phase_3_placebo-controlled_trial_SUCCEED_evaluating_the_mTOR_inhibitor_ridaforolimus_as_maintenance_therapy_in_advanced_sarcoma_patients_following_clinical_benefit_from_prior_standard_cytotoxic_chemotherapy_powerpoint_ppt_presentation
Icons create by Freepik from www.flaticon.com/